Unlocking the Potential of C10orf82: A Potential Drug Target and Biomarker for Chromosome 10 Open Reading Frame 82

Target Name: C10orf82

NCBI ID: G143379

C10orf82

Unlocking the Potential of C10orf82: A Potential Drug Target and Biomarker for Chromosome 10 Open Reading Frame 82

Introduction

Chromosome 10 (C10) is one of the chromosomes responsible for generating the major histocompatibility complex (MHC), which plays a crucial role in the immune system. Open reading frame (ORF) 82 is a non-coding RNA gene located on chromosome 10 that has been implicated in various cellular processes. C10orf82 has been identified as a potential drug target and biomarker due to its unique gene expression patterns and involvement in multiple biological processes.

C10orf82 Expression and Function

C10orf82 is a long non-coding RNA gene located on chromosome 10 at ORF 82. It has been shown to have a significant level of expression in various tissues and cell types, including brain, heart, and muscle. C10orf82 has also been detected in various human diseases, such as cancer, neurodegenerative diseases, and autoimmune disorders.

One of the most significant features of C10orf82 is its ability to interact with other genes. Studies have shown that C10orf82 can form complex with various transcription factors, including nuclear factor kappa B (NF-kappa-B), transcription factors YAP/TAZ, and RNA binding protein (RBP), etc. These interactions further reveal the important role of C10orf82 in gene expression and regulation.

C10orf82 as a Drug Target

C10orf82's unique expression patterns and interaction with other genes make it an attractive drug target. Several studies have shown that inhibiting C10orf82 expression can lead to therapeutic effects in various diseases. For example, experiments have shown that inhibiting C10orf82 expression can significantly improve the survival rate in cancer patients.

One of the potential benefits of targeting C10orf82 is its potential to act as a biomarker. Studies have shown that C10orf82 expression is significantly associated with the poor prognosis in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, C10orf82 expression has also been shown to be associated with various autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis.

C10orf82 as a Potential Biomarker

C10orf82 has also been identified as a potential biomarker for various diseases. Studies have shown that C10orf82 expression is significantly increased in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Additionally, C10orf82 has been shown to be involved in various biological processes that are altered in these diseases, such as inflammation, oxidative stress, and cellular stress.

C10orf82 as a Potential Drug Target and Biomarker

In conclusion, C10orf82 is a unique gene that has been identified as a potential drug target and biomarker. Its unique expression patterns and interaction with other genes make it an attractive target for therapeutic intervention. Further research is needed to fully understand the role of C10orf82 in various biological processes and its potential as a drug target and biomarker.

Protein Name: Chromosome 10 Open Reading Frame 82

The "C10orf82 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C10orf82 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets